Enjaymo
Payments companies reported to CMS as associated with Enjaymo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Enjaymo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Enjaymo
These are the largest totals companies reported as associated with Enjaymo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Trevor Feinstein | Fayetteville, GA | Hematology & Oncology | $110,219.51 |
| Catherine Broome | Washington, DC | Hematology & Oncology | $94,860.73 |
| Hillary Maitland | Charlottesville, VA | Hematology (Internal Medicine) | $79,597.97 |
| Jeremy Lorber | Beverly Hills, CA | Hematology & Oncology | $34,745.34 |
| Christopher Sirridge | Kansas City, KS | Hematology & Oncology | $32,134.41 |
| Wei Bai | Santa Maria, CA | Hematology & Oncology | $31,001.25 |
| Manish Dave | Edison, NJ | Hematology & Oncology | $26,834.56 |
| Daniel Landau | Orlando, FL | Hematology & Oncology | $22,947.82 |
| Ilene Weitz | Los Angeles, CA | Hematology (Internal Medicine) | $18,950.50 |
| Morey Blinder | Saint Louis, MO | Hematology (Internal Medicine) | $18,781.32 |
Prescribed Enjaymo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.